Hematopoietic growth factors in pediatrics
Related Experiment Video
Updated: Sep 30, 2026

Directed Differentiation of Primitive and Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells
Published on: November 1, 2017
1Department of Pediatrics, US Naval Hospital, Oakland, CA 94627-5000.
Insights
Recombinant hematopoietic growth factors like erythropoietin and colony-stimulating factors are effective in treating anemias and neutrophil disorders. These growth factors show promise for various pediatric and adult conditions, including chronic renal failure and cancer treatment side effects.
Area of Science:
- Biotechnology
- Hematology
- Immunology
Background:
- Hematopoietic growth factors are crucial for blood cell development.
- Recombinant human versions offer therapeutic potential.
Purpose of the Study:
- To review the clinical applications of human recombinant hematopoietic growth factors.
- To highlight their efficacy in various hematological conditions.
Main Methods:
- Review of existing clinical data and therapeutic outcomes.
- Analysis of efficacy in treating anemia and myeloid cell disorders.
Main Results:
- Recombinant human erythropoietin effectively treats anemia in chronic renal failure and premature infants.
- Granulocyte colony-stimulating factors benefit children with neutrophil production disorders and show promise in cancer therapy and HIV infections.
Conclusions:
- Human recombinant hematopoietic growth factors are valuable therapeutic agents.
- They offer significant clinical benefits for anemia, neutropenia, and other hematological conditions across different patient populations.
Abstract:
The human recombinant hematopoietic growth factors have attracted widespread interest because of their potential efficacy in a number of clinical settings. Recombinant human erythropoietin is now an established therapy to treat and prevent the anemia associated with chronic renal failure in children and adults. This agent also shows extraordinary promise to stimulate erythrocyte production and reduce transfusion requirements in premature infants. Granulocyte and granulocyte-macrophage colony-stimulating factors stimulate the production and function of myeloid cells and have provided major clinical benefit to children with congenital disorders of neutrophil production. The myeloid growth factors also show great promise in reducing the duration and severity of neutropenias associated with cytotoxic cancer treatment and in improving granulocyte production in patients with human immunodeficiency virus infections.
Related Concept Videos
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Differentiation of Common Myeloid Progenitor Cells
Regulation of Hematopoietic Stem Cells
Overview of Hematopoiesis
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

